Received Approval for Clinical Trial of Yunpi Huatan Tongqiao Granules
January 27, 2026
Source: drugdu
48
People's Finance News, Jan. 26: Kanion Pharmaceutical (600557) announced on Jan. 26 that it received a "Notice of Approval for Drug Clinical Trial" for Yunpi Huatan Tongqiao Granules from the National Medical Products Administration. The drug is intended to invigorate the spleen, resolve phlegm, and open orifices for treating children with adenoid hypertrophy with spleen deficiency and phlegm obstruction syndrome. While current treatments for children's adenoid hypertrophy include nasal corticosteroids, leukotriene receptor antagonists, antihistamines, and immunomodulators, there are no approved Chinese patent medicines on the market. If successful, this product could address an unmet clinical need.
https://finance.eastmoney.com/a/202601263630871910.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Strategic Collaboration with AstraZeneca, Potential Transaction Value Up to $18.5 Billion January 31, 2026
- Farsight Medical Announces First Patient Dosed in Phase II Clinical Trial of RN-0001, a World-First Therapy for Acute Pancreatitis January 31, 2026
- Boao Lecheng CGT project reaches 20 items! The first autologous NK therapy for eight types of cancer in China has been approved, costing 49,800 yuan per treatment January 31, 2026
- Yangtze River Pharmaceutical Group is ramping up its investment in the 10 billion yuan contrast agent market, aiming to challenge Hengrui January 31, 2026
- Simcere Pharmaceutical’s TL1A/IL-23p19 bispecific antibody goes global, partnering with Boehringer Ingelheim to expand the global inflammatory bowel disease market. January 31, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
